CDG Invest Growth sells its stake in Techniques Science-Santé

CDG Invest Growth (CIG), the private equity fund manager formerly known as CDG Capital Private Equity, and Techniques Science-Santé (T2S) announce the completion of the latter’s sale to a holding company majority owned by the Helios Investment Partners fund, according to a release.

The investment in T2S had been made in June 2016 through the Capmezzanine II fund.

Founded in 1992 by Abderraouf Sordo and his four partners, T2S offers complete solutions in radiology, oncology, ophthalmology, resuscitation, operating room and sterilization, and can meet more than 70% of a clinic’s equipment needs.

The Company also has a subsidiary, Cyclopharma, which is a pharmaceutical laboratory specialized in the production and distribution of contrast products for imaging and nuclear medicine.

To accelerate its development in Africa, T2S has created, in 2021, another subsidiary called T2S Africa based in Abidjan. The objective is to capitalize on the Company’s achievements in sub-Saharan Africa (Mauritania, Côte d’Ivoire, Mali, Guinea and Burkina Faso) and seize the numerous opportunities presented by the region to replicate the success of T2S in West Africa.

On the occasion of this sale, Abderraouf Sordo, Founder and CEO of T2S, said: “We are very proud to have reached this new milestone in the history of T2S, which is a consecration for the work of its women and men whose commitment and constant effort over 30 years has allowed us to earn the trust of our customers. This transaction, which has just been finalized, is also a moment for us to celebrate the outstanding achievements and transformation of our Company since we opened our capital to a private equity fund in 2016. We were fortunate to choose the best partner and we would not be where we are today without their support and value added over the past five years.”

Brahim Guessous, Partner at CDG Invest Growth, added: “We were honored to be part of this exciting venture with T2S which has been a great success in the healthcare sector. We are delighted to have made a great exit for our investors, but also to have succeeded in our mission to transform a Moroccan SME into a regional champion, a leader in its sector of activity and now part of a pan-African project. Our investment in T2S came after the promulgation of the law 131-13 in 2015, which allowed a significant injection of capital and the realization of many structuring projects in the health sector.

T2S has played a crucial role in this phase by accompanying key players in the sector to modernize and upgrade the national healthcare infrastructure. Finally, our investment in T2S has allowed us to cultivate a unique expertise in healthcare, one of our core sectors, which will continue to be of particular interest to investors in the coming years.